Long-term prognostic value of preoperative anemia in patients with colorectal cancer: A systematic review and meta-analysis

Surgical Oncology

Volumn 26, Issue 1, 2017, Pages 96-104

  Wilson, M J ^a,b   van Haaren, M ^c   Harlaar, J J ^d,e   Park, Hee Chul ^f   Bonjer, H J ^e   Jeekel, J ^b   Zwaginga, J J ^g,h   Schipperus, M ^a,i  

^a TRIP National hemovigilance and biovigilance office   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d Department of Radiation Oncology ^*  (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g SANQUIN RESEARCH   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ HAGA Ziekenhuis Den Haag   (Netherlands)

Author keywords

Colorectal; Preoperative anemia; Survival

Indexed keywords

ANEMIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; EMBASE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; WEB OF SCIENCE; COLORECTAL NEOPLASMS; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY; PREOPERATIVE CARE; PROGNOSIS;

ANEMIA; COLORECTAL NEOPLASMS; HUMANS; PREOPERATIVE CARE; PROGNOSIS;

EID: 85012170687     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2017.01.005     Document Type: Review

References (49)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136:5 (2015 Mar 1), E359–E386 PubMed PMID: 25220842.
2. [2] Edge, S., Byrd, D.R., Compton, C.C., et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. seventh ed., 2010, Springer, New York.
3. [3] Knight, K., Wade, S., Balducci, L., Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am. J. Med. 116:Suppl 7A (2004 Apr 5), 11S–26S PubMed PMID: 15050883.
4. [4] Weiss, G., Goodnough, L.T., Anemia of chronic disease. N. Engl. J. Med. 352:10 (2005 Mar 10), 1011–1023 PubMed PMID: 15758012.
5. [5] Steensma, D.P., Is anemia of cancer different from chemotherapy-induced anemia?. J. Clin. Oncol. 26:7 (2008 Mar 1), 1022–1024 PubMed PMID: 18227523.
6. [6] Graeber, T.G., Osmanian, C., Jacks, T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:6560 (1996 Jan 4), 88–91 PubMed PMID: 8538748.
7. [7] Harrison, L., Blackwell, K., Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 9:Suppl 5 (2004), 31–40 PubMed PMID: 15591420.
8. [8] Prosnitz, R.G., Yao, B., Farrell, C.L., et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 61:4 (2005 Mar 15), 1087–1095 PubMed PMID: 15752888.
9. [9] Vaupel, P., Briest, S., Hockel, M., Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med. Wochenschr 152:13–14 (2002), 334–342 PubMed PMID: 12168517.
10. [10] An, M.S., Yoo, J.H., Kim, K.H., et al. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. World J. Surg. Oncol., 13, 2015, 64 PubMed PMID: 25889520.
11. [11] Berardi, R., Braconi, C., Mantello, G., et al. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Ann. Oncol. 17:11 (2006 Nov), 1661–1664 PubMed PMID: 16968873.
12. [12] Qiu, M.Z., Yuan, Z.Y., Luo, H.Y., et al. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol. 31:4 (2010 Aug), 255–260 PubMed PMID: 20336401.
13. [13] van Halteren, H.K., Houterman, S., Verheij, C.D., et al. Anaemia prior to operation is related with poorer long-term survival in patients with operable rectal cancer. Eur. J. Surg. Oncol. 30:6 (2004 Aug), 628–632 PubMed PMID: 15256236.
14. [14] Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8:5 (2010), 336–341 PubMed PMID: 20171303.
15. [15] Tierney, J.F., Stewart, L.A., Ghersi, D., et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 2007, 16 PubMed PMID: 17555582.
16. [16] Colon Cancer Laparoscopic or Open Resection Study G, Buunen, M., Veldkamp, R., et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 10:1 (2009 Jan), 44–52 PubMed PMID: 19071061.
17. [17] Box, B., Lindsey, I., Wheeler, J.M., et al. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis. Colon Rectum 48:6 (2005 Jun), 1153–1160 PubMed PMID: 15868236.
18. [18] Cengiz, O., Kocer, B., Surmeli, S., et al. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma?. Med. Sci. Monit.(6), 2006 Jun, 12 CR240-247. PubMed PMID: 16733481.
19. [19] Fjortoft, I., Furnes, B., Hausken, T., et al. Pre-operative anaemia in colon cancer patients became normal after more than a year post-operatively but did not influence oncological outcome in the final analysis. Scand. J. Gastroenterol. 48:6 (2013 Jun), 663–671 PubMed PMID: 23534433.
20. [20] Giessen, C., Nagel, D., Glas, M., et al. Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer. Tumour Biol. 35:10 (2014 Oct), 10237–10248 PubMed PMID: 25027407.
21. [21] Giessen-Jung, C., Nagel, D., Glas, M., et al. Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. Tumour Biol. 36:10 (2015 Sep), 7897–7906 PubMed PMID: 25953265.
22. [22] Khan, A.A., Klonizakis, M., Shabaan, A., et al. Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers. Colorectal Dis. 15:10 (2013), 1232–1237 PubMed PMID: 23710579.
23. [23] Lee, H., Park, H.C., Park, W., et al. Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer. Radiat. Oncol. J. 30:3 (2012 Sep), 117–123 PubMed PMID: 23170290.
24. [24] Peng, Y., Wang, L., Gu, J., Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J. Surg. 37:1 (2013 Jan), 208–213 PubMed PMID: 23052808.
25. [25] van der Pas, M.H., Haglind, E., Cuesta, M.A., et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 14:3 (2013 Mar), 210–218 PubMed PMID: 23395398.
26. [26] Majek, O., Gondos, A., Jansen, L., et al. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PloS One, 8(7), 2013, e68077 PubMed PMID: 23861851.
27. [27] Caro, J.J., Salas, M., Ward, A., et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:12 (2001 Jun 15), 2214–2221 PubMed PMID: 11413508.
28. [28] Reynolds, T.Y., Rockwell, S., Glazer, P.M., Genetic instability induced by the tumor microenvironment. Cancer Res. 56:24 (1996 Dec 15), 5754–5757 PubMed PMID: 8971187.
29. [29] Leo, C., Giaccia, A.J., Denko, N.C., The hypoxic tumor microenvironment and gene expression. Semin. Radiat. Oncol. 14:3 (2004 Jul), 207–214 PubMed PMID: 15254863.
30. [30] Vamvakas, E.C., Blajchman, M.A., Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?. Blood 97:5 (2001 Mar 1), 1180–1195 PubMed PMID: 11222359.
31. [31] Amato, A., Pescatori, M., Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst. Rev., 2006 Jan 25 (1):CD005033. PubMed PMID: 16437512.
32. [32] Acheson, A.G., Brookes, M.J., Spahn, D.R., Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann. Surg. 256:2 (2012 Aug), 235–244 PubMed PMID: 22791100.
33. [33] Busch, O.R., Hop, W.C., Hoynck van Papendrecht, M.A., et al. Blood transfusions and prognosis in colorectal cancer. N. Engl. J. Med. 328:19 (1993 May 13), 1372–1376 PubMed PMID: 8292113.
34. [34] Harlaar, J.J., Gosselink, M.P., Hop, W.C., et al. Blood transfusions and prognosis in colorectal cancer: long-term results of a randomized controlled trial. Ann. Surg. 256:5 (2012 Nov), 681–686 discussion 686-687. PubMed PMID: 23095610.
35. [35] Adamson, J.W., Spivak, J.L., Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment. Surgery 115:1 (1994 Jan), 7–15 PubMed PMID: 8284765.
36. [36] Alghamdi, A.A., Albanna, M.J., Guru, V., et al. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J. Card. Surg. 21:3 (2006 May-Jun), 320–326 PubMed PMID: 16684074.
37. [37] Bohlius, J., Schmidlin, K., Brillant, C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:9674 (2009 May 2), 1532–1542 PubMed PMID: 19410717.
38. [38] Pascual, M., Bohle, B., Alonso, S., et al. Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J. Surg. Res. 183:1 (2013 Jul), 270–277 PubMed PMID: 23348072.
39. [39] Schrijvers, D., De Samblanx, H., Roila, F., et al. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 21:Suppl 5 (2010 May), v244–247 PubMed PMID: 20555090.
40. [40] Rizzo, J.D., Brouwers, M., Hurley, P., et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Clin. Oncol. 28:33 (2010 Nov 20), 4996–5010 PubMed PMID: 20975064.
41. [41] Keeler, B.D., Simpson, J.A., Ng, S., et al. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis. 16:10 (2014 Oct), 794–800 PubMed PMID: 24916374.
42. [42] Borstlap, W., Stellingwerf, M.E., Moolla, Z., et al. Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma a systematic review. Colorectal Dis, 17(12), 2015 Dec PubMed PMID: 26342151.
43. [43] Chua, A.C., Klopcic, B., Lawrance, I.C., et al. Iron: an emerging factor in colorectal carcinogenesis. World J. Gastroenterol. 16:6 (2010 Feb 14), 663–672 PubMed PMID: 20135713.
44. [44] Nelson, R.L., Iron and colorectal cancer risk: human studies. Nutr. Rev. 59:5 (2001 May), 140–148 PubMed PMID: 11396694.
45. [45] Knekt, P., Reunanen, A., Takkunen, H., et al. Body iron stores and risk of cancer. Int. J. Cancer 56:3 (1994 Feb 1), 379–382 PubMed PMID: 8314326.
46. [46] Edgren, G., Reilly, M., Hjalgrim, H., et al. Donation frequency, iron loss, and risk of cancer among blood donors. J. Natl. Cancer Inst. 100:8 (2008 Apr 16), 572–579 PubMed PMID: 18398098.
47. [47] Zacharski, L.R., Chow, B.K., Howes, P.S., et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J. Natl. Cancer Inst. 100:14 (2008 Jul 16), 996–1002 PubMed PMID: 18612130.
48. [48] Ilsley, J.N., Belinsky, G.S., Guda, K., et al. Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr. Cancer 49:2 (2004), 162–169 PubMed PMID: 15489209.
49. [49] Radulescu, S., Brookes, M.J., Salgueiro, P., et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep. 2:2 (2012 Aug 30), 270–282 PubMed PMID: 22884366. Epub 2012/08/14. eng.